Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease

NCT05210283 is registered in ClinicalTrials.gov with Exact Sciences Corporation as lead sponsor.

NCT NCT05210283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05210283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
Lead sponsor
Exact Sciences Corporation
Phase
Observational
Overall status
Active, not recruiting
Start date
December 15, 2021
Completion date
May 15, 2027
Enrollment
1,017 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer